Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
For locally advanced or recurrent metastatic breast cancer that is resistant to systemic therapy, radiotherapy (RT) may be considered as the preferred treatment option when the lesion is unresectable, or the patient is not suitable for surgery. This study aim to evelatuate the local control of radical dose RT or new RT technique (such as patially fractionated radiation therapy, SFRT) for the locally advanced or recurrent metastatic breast cancer.
Official title: A Prospective Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
29
Start Date
2026-06-30
Completion Date
2027-12-31
Last Updated
2026-06-29
Healthy Volunteers
No
Conditions
Interventions
Radical dose radiotherapy
Radical dose is delivered for the patients. SFRT is recommended for the patients with bulky tumor (such as ≥ 5cm). SFRT is delivered with 12-20Gy (1 fraction) followed by external beam radiation therapy (EBRT) with EQD2≥60Gy.
Locations (1)
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China